Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice.

While there has been much recent interest in the relationship between attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs), little has been reported about ADHD diagnostic subtypes, persistence of symptoms from childhood into adulthood, and substance of choice in individuals with substance use disorders (SUD+) and comorbid ADHD. To examine the prevalence and subtypes of ADHD in a group of SUD+ individuals, 136 inpatients with an SUD diagnosis (cocaine vs. alcohol vs. cocaine/alcohol) were administered a structured interview for ADHD. Of the SUD+ individuals, 32% met criteria for ADHD, and 35% of those with a childhood diagnosis of ADHD continued to have clinically significant symptoms into adulthood. There were no significant differences in the percentage of ADHD between the SUD+ groups divided by drug choice. Of ADHD subtypes, subjects with combined and inattentive types were significantly more likely to have symptoms continue into adulthood (p < or = .05) than the hyperactive/impulsive subtype. Patients with cocaine use were more likely to have ADHD in childhood only when compared to the alcohol or cocaine-alcohol groups. The findings of this study indicate that ADHD is prevalent in treatment-seeking substance users without difference in prevalence or subtype by drug choice.

How and why aztreonam works.

Aztreonam is the first monocyclic beta-lactam antibiotic (monobactam) to be tested clinically. Its synthetic structure determines specific areas of activity, including enhanced activity against Pseudomonas species, exceptional activity against gram-negative bacteria, stability to beta-lactamases and lack of activity against gram-positive bacteria--all of which can be directly related to its chemical composition. Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria. Most of these organisms are inhibited and killed at low concentrations of the drug. Aztreonam binds poorly to PBP sites of the aerobic gram-positive and anaerobic bacteria and consequently has relatively poor inhibitory effects against these bacteria. In vitro, minimum inhibition concentration (MIC) values against almost all of the Enterobacteriaceae and against Neisseria and Haemophilus strains are typically below 1 microgram per milliliter. MIC values against Pseudomonas aeruginosa of 8 micrograms per milliliter are comparable with those of other antipseudomonal beta-lactams and the acylureidopenicillins. As combination therapy with amino-glycosides, aztreonam acts in synergy against P. aeruginosa, Acinetobacter and gentamicin-resistant gram-negative rods. Aztreonam is widely distributed in the body tissues and fluids, and the average elimination half-life is 1.7 hours. Intramuscular dosing results in peak serum levels in approximately one hour, while intravenous dosing results in peak levels within five minutes. After a 2 gram dose given intravenously, MIC90 values for most of the Enterobacteriaceae are exceeded for eight hours, and those for P. aeruginosa, for almost six hours. The steady-state volume of distribution is approximately 0.18 liter per kilogram. Concentrations above the MIC90 for most gram-negative bacteria are also present within bone, prostate and cerebrospinal fluid. Between 60 and 70 per cent of the drug is excreted unchanged in the urine, resulting in concentrations approximating 3,000 micrograms per milliliter two hours after a 1 gram dose given intravenously. Serum clearance of aztreonam is directly proportional to creatinine clearance. Dosage adjustment must, therefore, be made in the presence of reduced clearance. Dosing varies between 0.5 and 2.0 grams every six to 12 hours, depending on the severity of the infection. The characteristics of aztreonam suggest that it is a useful nonnephrotoxic drug for treatment of aerobic gram-negative infection.

Traumatic aortocaval fistula: case report.

A gunshot wound to the right chest in a 21-year-old female resulted in an acute aortocaval fistula at the level of the diaphragm. An operative approach planned for maximal exposure, vascular control with intraluminal balloon catheters, and conservation of blood with an intraoperative autotransfusion system resulted in successful repair and long-term survival.

Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin.

Three broad-spectrum cephalosporins (cefotetan, moxalactam, and cefoxitin) proved effective in this randomized, prospective trial for treatment of 303 surgical patients with moderately severe regional peritonitis.

Ability of cancer patients' macrophages to kill autologous tumor targets. Effect of prostaglandin inhibitors on cytotoxicity.

Monocyte-derived macrophages isolated from the peripheral blood of 17 patients with cancer were studied for their cytotoxic effects on a sensitive allogeneic tumor target as well as autologous tumor cells. Macrophages from four of the cancer patients were cytotoxic towards the allogeneic tumor target. Five patients had macrophages which were cytotoxic towards the autologous targets. When indomethacin, a prostaglandin inhibitor, was added to the noncytotoxic macrophages during the cytotoxicity assay, macrophages from 5 of the 11 cancer patients studied became cytotoxic for the allogeneic target, and macrophages from 4 of the 11 patients became cytotoxic for the autologous tumor cells. However, it was also noted that those cancer patients who possessed cytotoxic macrophaged in the absence of indomethacin, became noncytotoxic towards the tumor cells after addition of indomethacin. These results indicate that addition of indomethacin to cytotoxic macrophages suppresses macrophage mediated cytotoxicity whereas addition of indomethacin to noncytotoxic macrophages greatly enhances macrophage mediated cytotoxicity. This theory was further substantiated when it was observed that the cytotoxic macrophages obtained from normal donors also became noncytotoxic for a sensitive tumor cell line after the addition of indomethacin during the cytotoxicity assay.

Extrahepatic biliary obstruction associated with pancreatitis.

A total of 40 patients with pancreatitis had associated extrahepatic biliary obstruction. Eighteen had biliary-induced pancreatitis. Comprehensive correction of the biliary tract disease, including cholecystectomy, common duct exploration and, when indicated, transduodenal sphincteroplasty, resulted in a high recovery rate (83%) with no recurrence of pancreatitis. Twenty-two patients had chronic pancreatitis with involvement of the terminal biliary tract by a long tapering stenosis. Nineteen of these patients had chronic fibrocalcific pancreatitis secondary to chronic alcohol abuse. In five patients, the stenosis produced a high grade obstruction which required biliary bypass with choledochoduodenostomy (four) or cholecystoduodenostomy (one). The remaining 14 patients maintained patency of the biliary tract following correction of the underlying pancreatic pathology. The latter consisted of drainage (nine) or resection (five) of 14 associated pseudocysts (present in 64% of the 22 patients), combined with side-to-side pancreaticojejunostomy to decompress an obstruction of the major pancreatic duct. In assessing the degree of terminal bile duct stenosis, calibration of the duct with Bakes dilators or rubber catheters was a useful aid. Two of the 22 patients ultimately proved to have carcinomas, producing obstruction of the pancreatic duct in the head of the gland. Both were treated initially with choledochoduodenostomy. This possibility must be considered in the management of these patients.

Oophorectomy in women with carcinoma of the colon and rectum.

Carcinoma of the colon and rectum metastasizes readily to the ovaries, and oophorectomy during operation upon the colon and rectum remains an effective surgical technique for precluding subsequent oophorectomy and, thereby, diminishing the morbidity of carcinoma of the colon and rectum in women. This procedure does not significantly affect the survival rate. Carcinoma of the ovary has become the fourth most common lethal cancer in women. Usually, the tumor is diagnosed after the development of ascites, mass and weight loss. The five year survival rate remains about 30 per cent. The incidence of carcinoma of the ovary in women with carcinoma of the colon and rectum is roughly five times the incidence of carcinoma of the ovary, that would be expected by chance. We believe the aforementioned observations strongly expand and reinforce the original proponents of prophylactic oophorectomy performed upon women with carcinoma of the colon and rectum and that, therefore, oophorectomy should be an integral part of operation upon the colon and rectum in women.